Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / IUGNF - Imugene begins dosing in cohort three of VAXINIA monotherapy dose escalation trial

IUGNF - Imugene begins dosing in cohort three of VAXINIA monotherapy dose escalation trial

Imugene Ltd

(NewsDirect)

Imugene Ltd (ASX:IMU) CEO Leslie Chong tells Proactive that thecompany has dosed the first patients in cohort three of itsintravenous (IV) and intratumoral (IT) monotherapy dose-escalationtrial for novel cancer-killing virus VAXINIA (also known asCF33-hNIS). The City of Hope-developed oncolytic virus has been shownto shrink colon, lung, breast, ovarian and pancreatic cancer tumoursin preclinical laboratory and animal models.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Stock Information
Company Name: Imugene Ltd
Stock Symbol: IUGNF
Market: OTC
Menu
IUGNF IUGNF Quote IUGNF Short IUGNF News IUGNF Articles IUGNF Message Board
Get IUGNF Alerts

News, Short Squeeze, Breakout and More Instantly...